Chiome Bioscience Inc. (4583) Stock Price

Kaiyom Bioscience is a company engaged in the research and development of antibody therapeutics. Antibody therapeutics bind to specific antigens to target cancer cells and disease-causing proteins, offering high therapeutic efficacy and safety. The company focuses on antibody drug discovery for diseases where current treatment satisfaction remains low.

Kaiyom Bioscience operates two business segments using its proprietary antibody development technology, the "ADLib® System": drug discovery and drug discovery support services. In drug discovery, the company conducts basic research through preclinical development of antibody therapeutics and out-licenses drug candidates to pharmaceutical companies. In drug discovery support services, the company provides antibody development services to pharmaceutical companies and research institutions.

In its drug discovery business, the company is developing antibody drug candidates including CBA-1205 and CBA-1535. CBA-1205 targets hepatocellular carcinoma, while CBA-1535 is a multispecific antibody designed to attack cancer cells. These candidates are expected to serve as therapeutic agents in disease areas with high unmet medical needs.

The drug discovery support business provides antibody expression and purification services, as well as antibody development services using the ADLib® System. Through these services, the company supports drug discovery research for pharmaceutical companies and research institutions while generating revenue from service fees. Kaiyom Bioscience aims for growth in the antibody therapeutics market through these business operations.

Kaiyom Bioscience is advancing the development of innovative antibody therapeutics based on its proprietary antibody discovery technology, the ADLib® System. The company focuses on creating new drugs for diseases with low treatment satisfaction and aims to contribute to medical fields with high unmet needs.

The company's growth strategy involves leveraging multiple antibody discovery technologies to increase the likelihood of acquiring lead antibodies. This approach enables the development of new treatment methods for serious diseases and addresses unmet medical needs. Additionally, through partnerships with pharmaceutical companies, the company provides solutions tailored to research and development requirements.

The medium-term management plan focuses on two clinical-stage development candidates: CBA-1205 and CBA-1535. These antibody drug candidates are expected to offer new treatment options in cancer therapy, with clinical trials underway to evaluate safety and efficacy. CBA-1205 is particularly expected to be effective against hepatocellular carcinoma and melanoma.

Furthermore, Kaiyom Bioscience is building a stable revenue base through its drug discovery support business. By providing high-quality antibody discovery services and expanding transactions with pharmaceutical companies, the company supports investment in its drug discovery operations. Going forward, the company aims for further growth through the expansion of its IDD-type business model.